中文摘要：

血管活性肠肽（VIP）是心肺系统最丰富的肽类物质之一，具有强大的抗炎、肺血管与气道舒张作用，以及免疫调节、调节气道分泌等广泛的生物学作用，可减缓COPD相关肺动脉高压（PH）的进展。然而，由于其血浆半衰期较短，给药途径困难，故临床有待进一步研究。本文就现阶段VIP对COPD相关PH治疗的研究进展作一综述。

英文摘要：

Vasoactive intestinal peptide （VIP） is one of the most abundant peptide in cardiopulmonary system,which has a wide range of biological effects, like a powerful anti-inflammatory effect,powerful vascular/ airway relaxant effect, as well as immune regulation and regulation airway secretion,can slow down chronic obstructive pulmonary disease （COPD） related pulmonary hypertension （PH） progress. However, because of its short plasma half-life, route of administration difficulties, so VIP need further study in the clinical use. In this paper,the present stage of COPD-related PH which is treated by VIP progress is reviewed.